Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.

Anu Osinusi, MD, discusses the findings examining bulevirtide as a standalone therapy and in combination with pegylated interferon alpha.

Vibrant Wellness’ Jason Barker, ND, outlines prevention measures, diagnostic red flags, and advances in multiplex testing for tick-borne diseases.

A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.

Current prevention strategies include two injectables for infants and young children, namely palivizumab and nirsevimab.

LA County confirms 165 cases since 2024 with 29 in 2025 alone, including individuals without known risk factors.

Atea Pharmaceuticals' investigational combination treatment of bemnifosbuvir and ruzasvir showed these results after an 8-week treatment regimen.

Jennifer Cohn, MD, MPH, calls for better data, drug access, and care tracking to address gaps in treatment.

Paul Offit, MD, offers insights on the state of measles today where some families are opting to believe treatment is a better option than vaccination. He also discusses the potential toxicity of vitamin A treatment, as well as the limitations of supportive treatment for the disease.

In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.

WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.

Jason Barker, ND, explains how in-house technology delivers highly sensitive specific and early detection of Borrelia infections and co-infections helping patients receive faster diagnosis and treatment

An "alarmingly" wide treatment gap for antimicrobial-resistant infections in under resourced countries is attributed to multiple factors including barriers to access.

Michigan dairy worker's infection is linked to widespread H5N1 outbreaks, as new findings suggest increased transmission risk and moderate disease in mammals.

De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.

The Centers for Disease Control and Prevention (CDC) investigates backyard poultry-linked outbreak across 6 states, while FDA issues tomato recall over separate contamination concerns.

Primaquine safely and effectively blocks malaria transmission across age-groups and different rates of regional transmission, leading to call for lower, pediatric-appropriate dose formulation.

US outbreaks account for 93% of cases, North Dakota sees first case since 2011, and the Americas Region reports over 2,300 infections.

Jason Barker, ND, details how Vibrant’s platform raises diagnostic sensitivity from 63% to 100%, ensuring more accurate detection and faster treatment for Lyme disease and tick-borne infections.

Sean Nguyen PharmD, BCIDP, medical director Shionogi, delves into the European cohort portion of the study and offers further information from the trial and some of its bigger clinical ramifications.

Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.

The National Foundation for Infectious Diseases (NFID) released its 2025 NFID State of Handwashing Report and found that many US adults forget or choose not to wash their hands at key times when germs can easily spread.

The INSPIRE 3 trial demonstrates that computerized order entry recommendation prompts can reduce empiric use of broad-spectrum antibiotics in favor of targeted treatment for skin and soft tissue infections.

Rising tick-borne illnesses due to warmer winters, strong hepatitis E vaccine efficacy during an outbreak, emerging fungal threats and resistance, and more.

The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.